Cite
HARVARD Citation
Castaño-Bonilla, T. et al. (2022). No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. Disease markers. p. . [Online].